This week's edition of the EuroBiotech Report brings fresh evidence that the U.S. biotech IPO boom has landed on European shores, with other companies from the stable of Circassia-backer Imperial Innovations considering going public and InDex Pharmaceuticals preparing to test the waters in Sweden. And more.
With London biotech Circassia clearing about $332 million in a record-breaking U.K. IPO, a spate of other European life sciences outfits sit stage left with eyes on the public markets, stoking hopes that the stateside fervor over drug developers could cross the ocean and line their pockets.
Now that it's steered its way successfully through the treacherous waters of a Phase II/III study for a new-and-improved drug for Parkinson's, Adamas Pharmaceuticals believes this is the right time to mount a $69 million IPO bid as it sets the stage for a pivotal trial.
With IPOs still booming, follow-on financings sizzling and venture capital rolling in at a steady pace, the biotech industry has been stocking up on billions of dollars in cash.
Horizon Discovery Group, which makes and sells tools for genomics research and personalized medicines, has set out to raise about $41.5 million on the AIM market on the London Stock Exchange.
The biotech IPO window is open, and Radius Health is preparing to see if it can make the leap and land on Wall Street with about $86 million in hand.
The antibiotics developer Achaogen has set its terms for a planned IPO, saying it will sell 5 million shares at $12 to $14 a share.
There were a few misfires on the biotech IPO front in the fourth quarter of 2013, but the National Venture Capital Association says it tallied 6 newly minted public drug developers in the period, winding up a big year.
The Woodcliff Lake, NJ-based company tweaks existing injectable drugs to make them preferable to the original therapies and says it is working on 6 advanced development programs with two approved products.
MacroGenics priced its upsized IPO on the high end of its range today, only to see its shares soar more than 50% on the biotech's debut.